“Integrating SeQure Dx into MaxCyte’s portfolio will allow us to leverage our expertise and drive advancements in the safety and precision of cell therapies,” Masoud said.
He emphasized MaxCyte’s commitment to both organic and inorganic growth, as it continues to develop cutting-edge tools for gene and cell engineering.
SeQure Dx’s Expertise in Gene Editing Validation
SeQure Dx specializes in assays that confirm gene editing accuracy and assess potential risks, which are crucial for advancing safe and effective cell and gene therapies. MaxCyte believes this expertise will enhance its support for therapy developers working on next-generation treatments.
Legal and Financial Details
- The acquisition was announced on the London Stock Exchange (LSE), where MaxCyte is dually listed alongside Nasdaq.
- Counsel information for the transaction was not immediately available.
With this acquisition, MaxCyte is reinforcing its position in the competitive gene editing space, ensuring it remains at the forefront of cell therapy advancements.
